“Keiretsu Forum takes a disciplined and comprehensive approach to deal screening and due diligence for their investors. Their process allows companies to access a large group of sophisticated investors, while allowing Keiretsu members to access quality deals. The enthusiasm Savara received has been tremendous; allowing us to proceed with a Phase II clinical trial in MRSA infected cystic fibrosis patients without the need for VC funding! As of October 2012, and with Keiretsu Forum’s 15 chapters taking the lead, Savara raised a little over $5m.”
CEO, Savara Pharmaceuticals, Inc.